QIAGEN

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell QIAGEN and other ETFs, options, and stocks.

About QGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. 

CEO
Thierry L. Bernard
CEOThierry L. Bernard
Employees
5,654
Employees5,654
Headquarters
Venlo, Limburg
HeadquartersVenlo, Limburg
Founded
1996
Founded1996
Employees
5,654
Employees5,654

QGEN Key Statistics

Market cap
7.13B
Market cap7.13B
Price-Earnings ratio
16.92
Price-Earnings ratio16.92
Dividend yield
0.76%
Dividend yield0.76%
Average volume
2.71M
Average volume2.71M
High today
$34.70
High today$34.70
Low today
$33.56
Low today$33.56
Open price
$33.56
Open price$33.56
Volume
4.31M
Volume4.31M
52 Week high
$57.82
52 Week high$57.82
52 Week low
$33.17
52 Week low$33.17

Stock Snapshot

With a market cap of 7.13B, QIAGEN(QGEN) trades at $34.70. The stock has a price-to-earnings ratio of 16.92 and currently yields dividends of 76.1%.

On 2026-05-01, QIAGEN(QGEN) stock moved within a range of $33.56 to $34.70. With shares now at $34.70, the stock is trading +3.4% above its intraday low and 0.0% below the session's peak.

Trading activity shows a volume of 4.31M, compared to an average daily volume of 2.71M.

The stock's 52-week range extends from a low of $33.17 to a high of $57.82.

The stock's 52-week range extends from a low of $33.17 to a high of $57.82.

QGEN News

TipRanks 18h
Qiagen price target lowered to $43 from $54 at Deutsche Bank

Deutsche Bank analyst Jan Koch lowered the firm’s price target on Qiagen (QGEN) to $43 from $54 and keeps a Buy rating on the shares. Unlock hedge fund-level d...

Simply Wall St 2d
Is Qiagen Offering An Opportunity After Its Recent Share Price Slump

If you are wondering whether Qiagen's current share price reflects its underlying worth, you are not alone. That question sits at the heart of this analysis. A...

Is Qiagen Offering An Opportunity After Its Recent Share Price Slump
TipRanks 3d
Qiagen Sets Date for Publication of 2025 Annual Financial Report

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

61%

of 23 ratings
Buy
39.1%
Hold
60.9%
Sell
0%

More QGEN News

TipRanks 3d
Qiagen Kept at Hold as Guidance Cut and QuantiFERON Weakness Offset H2 Rebound Hopes and Heighten Execution Risk

William Blair analyst Andrew Brackmann has maintained their neutral stance on QGEN stock, giving a Hold rating today. Claim 55% Off TipRanks Unlock hedge fund-l...

TipRanks 3d
Qiagen down 5% at $36.11 after Q1 pre-announcement, FY26 guidance cut

16:23 EDT Qiagen (QGEN) down 5% at $36.11 after Q1 pre-announcement, FY26 guidance cut Published first on TheFly – the ultimate source for real-time, market-mo...

TipRanks 4d
Qiagen reports Q1 preliminary EPS ‘at least’ 54c, consensus 54c

Reports Q1 preliminary revenue $492M, consensus $501.5M. “QIAGEN (QGEN) made important progress across many areas of the portfolio in the first quarter, led by...

People also own

Based on the portfolios of people who own QGEN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.